Adapting a population cost-effectiveness model for capecitabine-docetaxel combination therapy for metastatic breast cancer.

被引：0
|
作者：
Verma, S
Ilersich, AL
机构：
[1] F Hoffmann La Roche & Co Ltd, Hlth Outcomes Dept, Mississauga, ON, Canada
[2] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
265
引用
收藏
页码：253 / 253
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of capecitabine in combination with docetaxel versus docetaxel monotherapy in patients with advanced and/or metastatic breast cancer in France
    Lilliu, H
    Le Pen, C
    Priol, G
    Perez-Niddam, K
    Aultman, R
    Garrison, L
    VALUE IN HEALTH, 2003, 6 (06) : 626 - 626
  • [2] Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France
    Priol, G
    Maurel, F
    Le Pen, C
    BULLETIN DU CANCER, 2005, 92 (09) : 809 - 816
  • [3] Population based cost-effectiveness analysis of combination capecitabine and docetaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen
    Taylor, SM
    Barnett, J
    Chia, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S67 - S67
  • [4] Capecitabine in combination with docetaxel in the management of metastatic breast cancer
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    Psychogios, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Capecitabine plus docetaxel combination therapy -: Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma
    Verma, S
    Maraninchi, D
    O'Shaughnessy, J
    Jamieson, C
    Jones, S
    Martín, M
    McKendrick, J
    Miles, D
    Twelves, C
    Hornberger, J
    CANCER, 2005, 103 (12) : 2455 - 2465
  • [6] Capecitabine maintenance therapy after docetaxel/capecitabine combination chemotherapy in patients with metastatic breast cancer
    Gursoy, Pinar
    Surmeli, Zeki Gokhan
    Cakar, Burcu
    Arslan, Cagatay
    Zengel, Baha
    Karaca, Burcak
    Sezgin, Canfeza
    Karabulut, Bulent
    Sanli, Ulus Ali
    Uslu, Ruchan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Cost-effectiveness of nanoparticle albumin-bound paclitaxel versus docetaxel in the treatment of metastatic breast cancer.
    Gradishar, W
    Vishalpura, T
    Franklin, M
    Bramley, T
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S220 - S221
  • [8] Cost-effectiveness for metastatic colorectal cancer.
    Yao, Linli
    Han, Jiaqi
    She, Longjiang
    Ding, Dong
    Liao, Mengting
    Hu, Huabin
    Zeng, Shan
    Shen, Liangfang
    Huang, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment. in patients with metastatic breast cancer
    Surmeli, Zeki Gokhan
    Varol, Umut
    Cakar, Burcu
    Degirmenci, Mustafa
    Arslan, Cagatay
    Piskin, Gonul Demir
    Zengel, Baha
    Karaca, Burcak
    Sanli, Ulus Ali
    Uslu, Ruchan
    ONCOLOGY LETTERS, 2015, 10 (04) : 2598 - 2602
  • [10] A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer.
    Puglisi, F
    Scalone, S
    Minisini, AM
    Mansutti, M
    Crivellari, D
    Buonadonna, A
    Zanetti, M
    Ermacora, P
    Piga, A
    Veronesi, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 78S - 78S
12345